medigraphic.com
ISSN 2539-0859 (Electronic)
ISSN 0120-8411 (Print)
Asociación Colombiana de Otorrinolaringología y Cirugía de Cabeza y cuello, Maxilofacial y Estética Facial (ACORL)

2025, Number 1

<< Back Next >>

Acta de Otorrinolaringología CCC 2025; 53 (1)

Usage profile of vestibular sedatives for the treatment of peripheral vertigo in Colombia

Campos-Mahecha AM, Rojas-Herrera LM

Language: Spanish
References: 62
Page: 31-40
PDF size: 503.40 Kb.


ABSTRACT

Introduction: The inappropriate use of vestibular sedatives is associated with an increased risk of falls, hospitalizations, high costs, adverse events, and poorer clinical outcomes. Therefore, knowing medication consumption and its variation over time is crucial. The objective was to establish the usage profile of vestibular sedatives in the outpatient treatment of peripheral vertigo in patients over 18 years old insured under the Colombian Social Security System, from July 2021 to June 2022. Methods: A cross-sectional descriptive study used information from a medication dispensation database, evaluating sociodemographic, pharmacological, and clinical variables. Univariate and bivariate descriptive analysis were performed to establish a possible relationship between active ingredients, polypharmacy, interactions, synergy, and the prescribing doctor. Results: 22,776 patients were identified, with a median age of 56 years, where 64.65% were female. Concerning the usage profile of vestibular sedatives: Dimenhydrinate, had the highest dispensation at 72.30%, indicated for paroxysmal vertigo and other peripheral vertigos, followed by Betahistine at 37,50%, diphenhydramine at 6.50%, and Meclizine at 0.40%. Prolonged use of any vestibular sedative was observed in 7.0%, 74.45% exhibited polypharmacy, and the synergy summation was 4.80%. Conclusion: Dimenhydrinate had the highest prescription rate in Colombia. The significant percentage of polypharmacy and pharmacological management of benign paroxysmal vertigo is noteworthy. Therefore, individualized treatment is suggested, considering potential adverse reactions.


REFERENCES

  1. Bhattacharyya N, Gubbels SP, Schwartz SR, Edlow JA,El-Kashlan H, Fife T, et al. Clinical practice guideline:Benign paroxysmal positional vertigo (update). OtolaryngolHead Neck Surg . 2017;156(3_suppl):S1–47. doi: 10.1177/0194599816689667

  2. Davis, Adrian & Moorjani, Padma. (2003). The Epidemiologyof Hearing and Balance Disorders. Textbook of AudiologicalMedicine. 10.1201/b14730-8.

  3. Welgampola MS, Bradshaw AP, Halmagyi GM. Assessment ofthe Vestibular System: History and Physical Examination. AdvOtorhinolaryngol. 2019;82:1-11. doi: 10.1159/000490267

  4. Neuhauser HK. The epidemiology of dizziness and vertigo. En:Handbook of Clinical Neurology. Elsevier; 2016. p. 67–82.

  5. Muelleman T, Shew M, Subbarayan R, Shum A, Sykes K,Staecker H, et al. Epidemiology of dizzy patient populationin a neurotology clinic and predictors of peripheral etiology.Otol Neurotol . 2017;38(6):870- 5. doi: 10.1097/MAO.0000000000001429

  6. Murphy C, Reinhardt C, Linehan D, Katiri R, O’Connor A.A review of primary care referrals for patients with dizzinessand vertigo: prevalence and demographics. Ir J Med Sci .2022;191(1):385- 9. doi: 10.1007/s11845-021-02575-6

  7. Harun A, Agrawal Y. The use of fall risk increasing drugs(FRIDs) in patients with dizziness presenting to a neurotologyclinic. Otol Neurotol . 2015;36(5):862–4. doi: 10.1097/mao.0000000000000742

  8. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, MitchellAA. Recent patterns of medication use in the ambulatory adultpopulation of the United States: the Slone survey. JAMA .2002;287(3):337–44. doi: 10.1001/jama.287.3.337

  9. Herings RM, Stricker BH, de Boer A, Bakker A, SturmansF. Benzodiazepines and the risk of falling leading to femurfractures. Dosage more important than elimination half-life.Arch Intern Med. 1995;155(16):1801-7.

  10. Tinetti ME, McAvay GJ, Fried TR, Allore HG, Salmon JC,Foody JM, et al. Health outcome priorities among competingcardiovascular, fall injury, and medication-related symptomoutcomes. J Am Geriatr Soc. 2008;56(8):1409-16. doi:10.1111/j.1532-5415.2008.01815.x

  11. Kasbekar AV, Mullin N, Morrow C, Youssef AM, Kay T, LesserTH. Development of a physiotherapy-led balance clinic: theAintree model. J Laryngol Otol. 2014;128(11):966-71. doi:10.1017/S0022215114002060

  12. Gurley KL, Edlow JA. Acute Dizziness. Semin Neurol.2019;39(1):27-40. doi: 10.1055/s-0038-1676857

  13. Royal College of Physicians. Hearing and Balance Disorders:Achieving Excellence in Diagnosis and Management. Reportof a Working Party. London (United Kingdom): Royal Collegeof Physicians. 2007;iii-65.

  14. Burrows L, Lesser TH, Kasbekar AV, Roland N, Billing M.Independent prescriber physiotherapist led balance clinic:the Southport and Ormskirk pathway. J Laryngol Otol.2017;131(5):417-424. doi: 10.1017/S0022215117000342

  15. Trinidade A, Yung MW. Consultant-led, multidisciplinarybalance clinic: process evaluation of a specialist model of carein a district general hospital. Clin Otolaryngol. 2014;39(2):95-101. doi: 10.1111/coa.12236

  16. WHO Collaborating Centre for Drug Statistics Methodology(Internet). ATC/DDD Index 2024. Who.int. [citado el 16 demayo de 2023]. Disponible en: https://atcddd.fhi.no/atc_ddd_index/updates_included_in_the_atc_ddd_index/

  17. The selection of essential drugs: report of a WHO expert committee. World Health Organ Tech Rep Ser. 1977;(615):1-36.

  18. Lee D, Bergman U. Studies of drug utilization. In: BL Strom,SF Kimmel, S Hennessy (eds). Pharmacoepidemiology, 5.aedición. John Wiley, Chichester, UK, 2012; 379–401.

  19. Bergamasco A, Arredondo Bisono T, Castillon G, Moride Y.Drug Utilization Studies in Latin America: A Scoping Reviewand Survey of Ethical Requirements. Value Health Reg Issues.

  20. 2018;17:189-193. doi: 10.1016/j.vhri.2018.09.00320. Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. Whatis polypharmacy? A systematic review of definitions. BMCGeriatr. 2017;17(1):230. doi: 10.1186/s12877-017-0621-2

  21. Dyhrfjeld-Johnsen J, Attali P. Management of peripheral vertigowith antihistamines: New options on the horizon. Br J ClinPharmacol. 2019;85(10):2255-2263. doi: 10.1111/bcp.14046

  22. Iwasaki S, Yamasoba T. Dizziness and Imbalance in theElderly: Age-related Decline in the Vestibular System. AgingDis. 2014;6(1):38-47. doi: 10.14336/AD.2014.0128

  23. Lin E, Aligene K. Pharmacology of balance and dizziness.NeuroRehabilitation. 2013;32(3):529-42. doi: 10.3233/NRE-130875

  24. Spiegel R, Rust H, Baumann T, Friedrich H, Sutter R, Göldlin M,et al. Treatment of dizziness: an interdisciplinary update. SwissMed Wkly. 2017;147:w14566. doi: 10.4414/smw.2017.14566

  25. Dunlap PM, Khoja SS, Whitney SL, Freburger JK.Assessment of Health Care Utilization for Dizziness inAmbulatory Care Settings in the United States. Otol Neurotol.2019;40(9):e918-e924. doi: 10.1097/MAO.0000000000002359

  26. Lee C, Jones TA. Neuropharmacological Targets for DrugAction in Vestibular Sensory Pathways. J Audiol Otol.2017;21(3):125-132. doi: 10.7874/jao.2017.00171

  27. Soto E, Vega R, Seseña E. Neuropharmacological basisof vestibular system disorder treatment. J Vestib Res.2013;23(3):119-37. doi: 10.3233/VES-130494

  28. Casani AP, Gufoni M, Capobianco S. Current Insights intoTreating Vertigo in Older Adults. Drugs Aging. 2021;38(8):655-670. doi: 10.1007/s40266-021-00877-z

  29. Gurumukhani JK, Patel DM, Shah SV, Patel MV, Patel MM,Patel AV. Negative Impact of Vestibular Suppressant Drugs onProvocative Positional Tests of BPPV: A Study from the WesternPart of India. Ann Indian Acad Neurol. 2021;24(3):367-371.doi: 10.4103/aian.AIAN_413_20

  30. Hülse R, Biesdorf A, Hörmann K, Stuck B, Erhart M, Hülse M,et al. Peripheral Vestibular Disorders: An Epidemiologic Surveyin 70 Million Individuals. Otol Neurotol. 2019;40(1):88-95.doi: 10.1097/MAO.0000000000002013

  31. Hunter BR, Wang AZ, Bucca AW, Musey PI Jr, StrachanCC, Roumpf SK, et al. Efficacy of Benzodiazepines orAntihistamines for Patients With Acute Vertigo: A SystematicReview and Meta-analysis. JAMA Neurol. 2022;79(9):846-855. doi: 10.1001/jamaneurol.2022.1858

  32. Zwergal A, Strupp M, Brandt T. Advances in pharmacotherapy of vestibular and ocular motor disorders. Expert Opin Pharmacother. 2019;20(10):1267-1276. doi: 10.1080/14656566.2019.1610386

  33. Michel L, Laurent T, Alain T. Rehabilitation of dynamic visualacuity in patients with unilateral vestibular hypofunction:earlier is better. Eur Arch Otorhinolaryngol. 2020;277(1):103-113. doi: 10.1007/s00405-019-05690-4

  34. Schappert SM. National Ambulatory Medical Care Survey:1989 summary. Vital Health Stat 13. 1992;(110):1-80.

  35. Hanley K, O’Dowd T, Considine N. A systematic review of vertigo in primary care. Br J Gen Pract. 2001 Aug;51(469):666-71.

  36. Nsson R J, Sixt E, Landahl S, Rosenhall U. Prevalence ofdizziness and vertigo in an urban elderly population. J VestibRes. 2004;14:47–52.

  37. Furman JM, Raz Y, Whitney SL. Geriatric vestibulopathyassessment and management. Curr Opin OtolaryngolHead Neck Surg. 2010;18(5):386-91. doi: 10.1097/MOO.0b013e32833ce5a6

  38. Ribeiro KF, Oliveira BS, Freitas RV, Ferreira LM, Deshpande N,Guerra RO. Effectiveness of Otolith Repositioning Maneuversand Vestibular Rehabilitation exercises in elderly people withBenign Paroxysmal Positional Vertigo: a systematic review.Braz J Otorhinolaryngol. 2017;84(1):109–18. doi: 10.1016/j.bjorl.2017.06.003

  39. Vaduva C, Estéban-Sánchez J, Sanz-Fernández R, Martín-Sanz E. Prevalence and management of post-BPPV residualsymptoms. Eur Arch Otorhinolaryngol. 2018;275(6):1429-1437. doi: 10.1007/s00405-018-4980-x

  40. Lynn S, Pool A, Rose D, Brey R, Suman V. Randomized trial of the canalith repositioning procedure. Otolaryngol Head Neck Surg. 1995;113(6):712-20. doi: 10.1016/S0194-59989570010-2

  41. Burton MJ, Eby TL, Rosenfeld RM. Extracts from the CochraneLibrary: modifications of the Epley (canalith repositioning)maneuver for posterior canal benign paroxysmal positionalvertigo. Otolaryngol Head Neck Surg. 2012;147(3):407-11.doi: 10.1177/0194599812457134

  42. Hain TC, Uddin M. Pharmacological treatment of vertigo.CNS Drugs. 2003;17(2):85-100. doi: 10.2165/00023210-200317020-00002

  43. Shih RD, Walsh B, Eskin B, Allegra J, Fiesseler FW, Salo D,et al. Diazepam and Meclizine Are Equally Effective in theTreatment of Vertigo: An Emergency Department RandomizedDouble-Blind Placebo-Controlled Trial. J Emerg Med.2017;52(1):23-27. doi: 10.1016/j.jemermed.2016.09.016

  44. Lacour M, van de Heyning PH, Novotny M, TighiletB. Betahistine in the treatment of Ménière’s disease.Neuropsychiatr Dis Treat. 2007;3(4):429-40.

  45. Tighilet B, Léonard J, Watabe I, Bernard-Demanze L, Lacour M.Betahistine Treatment in a Cat Model of Vestibular Pathology:Pharmacokinetic and Pharmacodynamic Approaches. FrontNeurol. 2018;9:431. doi: 10.3389/fneur.2018.00431

  46. Yu L, Zhang X-Y, Cao S-L, Peng S-Y, Ji D-Y, Zhu J-N, et al. Na(+)-Ca(2+) exchanger, leak K(+) channel and hyperpolarization-activated cyclic nucleotide-gated channel comediate thehistamine-induced excitation on rat inferior vestibular nucleusneurons. CNS Neurosci Ther . 2016;22(3):184–93. doi: 10.1111/cns.12451

  47. Haas H, Panula P. The role of histamine and the tuberomamillarynucleus in the nervous system. Nat Rev Neurosci. 2003;4(2):121-30. doi: 10.1038/nrn1034

  48. Botta L, Mira E, Valli S, Zucca G, Benvenuti C, Fossati A, etal. Effects of betahistine and of its metabolites on vestibularsensory organs. Acta Otorhinolaryngol Ital. 2001;21(3 Suppl66):24-30.

  49. Murdin L, Hussain K, Schilder AG. Betahistine for symptoms ofvertigo. Cochrane Database Syst Rev. 2016;2016(6):CD010696.doi: 10.1002/14651858.CD010696.pub2

  50. Casani AP, Navari E, Guidetti G, Lacour M. Good ClinicalApproach: Delphi Consensus for the Use of Betahistine inMenière’s Disease. Int J Otolaryngol. 2018;2018:5359208. doi:10.1155/2018/5359208

  51. James AL, Burton MJ. Betahistine for Menière’sdisease or syndrome. Cochrane Database Syst Rev.2001;2001(1):CD001873. doi: 10.1002/14651858.CD001873

  52. Adrion C, Fischer CS, Wagner J, Gürkov R, Mansmann U,Strupp M; BEMED Study Group. Efficacy and safety ofbetahistine treatment in patients with Meniere’s disease:primary results of a long term, multicentre, double blind,randomised, placebo controlled, dose defining trial (BEMEDtrial). BMJ. 2016;352:h6816. doi: 10.1136/bmj.h6816

  53. Nauta JJ. Meta-analysis of clinical studies with betahistinein Ménière’s disease and vestibular vertigo. Eur ArchOtorhinolaryngol. 2014;271(5):887-97. doi: 10.1007/s00405-013-2596-8

  54. Della Pepa C, Guidetti G, Eandi M. Betahistine in thetreatment of vertiginous syndromes: a meta-analysis. ActaOtorhinolaryngol Ital. 2006;26(4):208-15.

  55. Strupp M, Kraus L, Schautzer F, Rujescu D. Menière’sdisease: combined pharmacotherapy with betahistine and theMAO-B inhibitor selegiline-an observational study. J Neurol.2018;265(Suppl 1):80-85. doi: 10.1007/s00415-018-8809-8. Retraction in: J Neurol. 2020;267(4):1225. doi: 10.1007/s00415-020-09791-7

  56. Di Mizio G, Marcianò G, Palleria C, Muraca L, Rania V,Roberti R, et al. Drug-Drug Interactions in Vestibular Diseases,Clinical Problems, and Medico-Legal Implications. Int JEnviron Res Public Health. 2021;18(24):12936. doi: 10.3390/ijerph182412936

  57. Gutiérrez-Valencia M, Izquierdo M, Cesari M, Casas-HerreroÁ, Inzitari M, Martínez-Velilla N. The relationship betweenfrailty and polypharmacy in older people: A systematic review.Br J Clin Pharmacol. 2018;84(7):1432-1444. doi: 10.1111/bcp.13590

  58. Pit SW, Byles JE, Henry DA, Holt L, Hansen V, Bowman DA.A Quality Use of Medicines program for general practitionersand older people: a cluster randomised controlled trial. MedJ Aust. 2007;187(1):23-30. doi: 10.5694/j.1326-5377.2007.tb01110.x

  59. Chimirri S, Aiello R, Mazzitello C, Mumoli L, Palleria C,Altomonte M, et al. Vertigo/dizziness as a Drugs’ adversereaction. J Pharmacol Pharmacother. 2013;4(Suppl 1):S104-9.doi: 10.4103/0976-500X.120969

  60. Kim HA, Bisdorff A, Bronstein AM, Lempert T, Rossi-IzquierdoM, Staab JP, et al. Hemodynamic orthostatic dizziness/vertigo:Diagnostic criteria. J Vestib Res. 2019;29(2-3):45-56. doi:10.3233/VES-190655

  61. Basura GJ, Adams ME, Monfared A, Schwartz SR, Antonelli PJ,Burkard R, et al. Clinical Practice Guideline: Ménière’s Disease.Otolaryngol Head Neck Surg. 2020;162(2_suppl):S1-S55. doi:10.1177/0194599820909438

  62. 62.Akutsu, T., Kobayashi, K., Sakurada, K., Ikegaya, H.,Furihata, T., & Chiba, K. (2007). Identification of HumanCytochrome P450 Isozymes Involved in DiphenhydramineN-Demethylation. Drug Metabolismand Disposition, 35(1), 72 LP – 78. https://doi.org/10.1124/dmd.106.012088




2020     |     www.medigraphic.com